# Nuclide record michael-morris (person). Data CC BY-NC 4.0, attribute "Data from Nuclide (nuclide.cc)". Whole corpus: https://nuclide.cc/api/v1/nuclide.nt
@prefix schema: <https://schema.org/> .
@prefix nuclide: <https://nuclide.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://nuclide.cc/people/michael-morris/>
  a schema:Person ;
  nuclide:kind "person" ;
  schema:identifier "michael-morris" ;
  schema:name "Michael J. Morris"@en ;
  schema:description "Principal investigator of the VISION trial that made lutetium-PSMA a standard prostate cancer treatment."@en ;
  schema:url <https://nuclide.cc/people/michael-morris/> ;
  schema:dateModified "2026-09-08"^^xsd:date ;
  schema:citation <https://www.mskcc.org/cancer-care/doctors/michael-morris>, <https://pubmed.ncbi.nlm.nih.gov/?term=Morris%20MJ%5BAuthor%5D> ;
  schema:jobTitle "Prostate Cancer Section Head, Genitourinary Oncology Service" ;
  nuclide:related <https://nuclide.cc/isotopes/lu-177/> ;
  nuclide:indications <https://nuclide.cc/indications/prostate/> ;
  nuclide:technologies <https://nuclide.cc/technologies/radioligand-therapy/>, <https://nuclide.cc/technologies/psma-pet/> ;
  nuclide:targets <https://nuclide.cc/targets/psma/> ;
  nuclide:drugs <https://nuclide.cc/drugs/pluvicto/> ;
  nuclide:institutions <https://nuclide.cc/institutions/mskcc/> ;
  nuclide:trials <https://nuclide.cc/trials/vision/>, <https://nuclide.cc/trials/psmafore/> ;
  schema:affiliation <https://nuclide.cc/institutions/mskcc/> .